Typically, the first full blog of the year reviews returns of benchmark index ETFs and opines on what prevailed in the past year through five years, then provides analysis that could provide insights into the future for US equities and other asset classes. This year is no different in that respect. Financial Advisory Services based … Read more
I will often feature stocks rated buy or strong buy in highly rated sectors. This one is a departure. The healthcare sector is most commonly represented by the Select Sector SPDR Healthcare ETF, XLV. It faced a challenging year in 2024, underperforming the S&P 500 Index by a staggering 22.4%. This massive performance shortfall resulted … Read more
The events of the past twelve months focused a lot of attention on amazing and life-altering developments made possible by the global biotech industry. Although the major names we heard were Pfizer, AstraZeneca, Johnson & Johnson and Moderna, only the last was where the original research and patents that produced the CoVid-19 vaccines were developed. … Read more